UNSPSC 51292802: Amoxapine

This classification denotes a tricyclic antidepressant with the molecular formula C17H16ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R63VQ857OT, chemically known as 2-chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine but generally known as amoxapine, which bears US NIH Compound Identifier 2170. Amoxapine most often comes in base and acetate forms. European Medicines Agency schedules Amoxapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05479MIG.

UNSPSC 51292802 Amoxapine, a Commodity code, nominally designates a specific tricyclic antidepressant pharmaceutical, but recent state and local procurement activity under this code shows minimal relevance to the drug itself. Instead, the code tag appears in opportunities broadly soliciting pharmaceuticals, over-the-counter products, and health-related supplies — naloxone and drug deactivation systems, generic multi-source drugs and OTC items, and therapeutic pharmacy initiatives — suggesting the code is used as a catch-all pharmaceutical family marker rather than a line-item SKU. State and local government buyers under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multi-state and multi-jurisdictional networks. The work being solicited ranges from direct procurement of specific health commodities (naloxone kits and drug disposal systems) to framework agreements that establish master contracts with pharmaceutical wholesalers and manufacturers serving entire state and county health systems.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission released RFI HHS0017013 on April 3, 2026, to gather vendor intelligence on direct-to-manufacturer prescription programs before issuing a formal RFP. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (solicitation S1070000015802) on January 20, 2026, with a March 26, 2026 response deadline to establish multi-award contracts for generic pharmaceuticals and OTC products through three authorized wholesalers, with contract effectiveness July 1, 2026. The MMCAP procurement requires cGMP and Drug Supply Chain Security Act certification, $5 million commercial general liability insurance, and pricing weighted 75 percent on competitiveness.